Renal amyloidosis medical therapy
|
Renal amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Template:Renal amyloidosis On the Web |
|
American Roentgen Ray Society Images of Renal amyloidosis medical therapy |
|
Risk calculators and risk factors for Renal amyloidosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2] Omer Kamal, M.D. [2]
Overview
The mainstay of treatment for Renal amyloidosis is to decrease the production or increase clearing of amyloid. Pharmacologic medical therapies for Renal amyloidosis include Colchicine, Azathioprine, Dimethylsulfoxide, Chlorambucil, Methotrexate, Cyclophosphamide andTNF-alpha antagonists (ie, etanercept, infliximab, and adalimumab).
Medical Therapy
- Pharmacologic medical therapies for Renal amyloidosis include
- Colchicine [1][2][3]
- Azathioprine
- Dimethylsulfoxide[4][5]
- Chlorambucil
- Methotrexate
- Cyclophosphamide [6][7]
- TNF-alpha antagonists (ie, etanercept, infliximab, and adalimumab)[8][9][10][11]
References
- ↑ Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M (1992). "Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever". Nephron. 60 (4): 418–22. doi:10.1159/000186801. PMID 1584316.
- ↑ Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R, Langevitz P, Livneh A (February 2004). "Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization". Semin. Arthritis Rheum. 33 (4): 273–82. PMID 14978665.
- ↑ Tan AU, Cohen AH, Levine BS (March 1995). "Renal amyloidosis in a drug abuser". J. Am. Soc. Nephrol. 5 (9): 1653–8. PMID 7780053.
- ↑ Iwakiri R, Sakemi T, Fujimoto K (October 1999). "Dimethylsulfoxide for renal dysfunction caused by systemic amyloidosis complicating Crohn's disease". Gastroenterology. 117 (4): 1031–2. PMID 10576978.
- ↑ Amemori S, Iwakiri R, Endo H, Ootani A, Ogata S, Noda T, Tsunada S, Sakata H, Matsunaga H, Mizuguchi M, Ikeda Y, Fujimoto K (May 2006). "Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review". J. Gastroenterol. 41 (5): 444–9. doi:10.1007/s00535-006-1792-3. PMID 16799886.
- ↑ Chevrel G, Jenvrin C, McGregor B, Miossec P (July 2001). "Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide". Rheumatology (Oxford). 40 (7): 821–5. PMID 11477289.
- ↑ Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S (December 2003). "Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis". Clin. Rheumatol. 22 (6): 371–5. doi:10.1007/s10067-003-0763-9. PMID 14677008.
- ↑ Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X (July 2003). "Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy". Arthritis Rheum. 48 (7): 2019–24. doi:10.1002/art.11163. PMID 12847696.
- ↑ Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, García-Vicuña R, González-Mari MV, Laffón A, García-Vicuña R (May 2005). "Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists". Am. J. Med. 118 (5): 552–6. doi:10.1016/j.amjmed.2005.01.028. PMID 15866260.
- ↑ Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M (December 2010). "Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis". Clin. Rheumatol. 29 (12): 1395–401. doi:10.1007/s10067-010-1469-4. PMID 20440529.
- ↑ Keersmaekers T, Claes K, Kuypers DR, de Vlam K, Verschueren P, Westhovens R (May 2009). "Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis". Ann. Rheum. Dis. 68 (5): 759–61. doi:10.1136/ard.2008.095505. PMID 19366896.
- ↑ Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (May 2002). "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis". Nature. 417 (6886): 254–9. doi:10.1038/417254a. PMID 12015594.
- ↑ Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB (March 2010). "Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis". Br. J. Haematol. 148 (5): 760–7. doi:10.1111/j.1365-2141.2009.08036.x. PMID 20064157.